

## Abteilungsbesprechung Februar 2023

**02.02.2023**

Klinischer Teil:

**Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies**

DOI: 10.1200/CCI.21.00126

Referent: A. Seehausen

Wissenschaftlicher Teil:

**Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial**

DOI: 10.1186/s13046-022-02510-2

Referentin: Friederike Klauk

**09.02.2023**

Klinischer Teil:

**Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results**

DOI: 10.1002/ajh.25238

Referent: C. Wittke

Wissenschaftlicher Teil:

**Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy**

DOI: 10.1038/s41375-022-01746-3

Referentin: Luisa Brock

**16.02.2023:**

Klinischer Teil:

**Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study**

DOI: <https://doi.org/10.1007/s00277-023-05087-8>

Referent: C. Kiefel

Wissenschaftlicher Teil:

**Design, synthesis, and biological evaluation of nitroisoxazolecontaining spiro[pyrrolidin-oxindole] derivatives as novel glutathione peroxidase 4/mouse double minute 2 dual inhibitors that inhibit breast adenocarcinoma cell proliferation**

DOI: 10.1016/j.ejmech.2021.113359

Referentin: Annika  
Eichhorst

**23.02.2023:**

Klinischer Teil:

**Overall Survival with Brentuximab Vedotin  
in Stage III or IV Hodgkin's Lymphoma**

DOI: 10.1056/NEJMoa2206125

Referentin: U. Langenkamp

Wissenschaftlicher Teil:

**EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that  
promotes temozolomide resistance in glioblastoma**

DOI: 10.1038/s41388-022-02570-w

Referent: Thomas Freitag